Advice
Following a full submission
levetiracetam (Keppra®) is not recommended for use within NHS Scotland as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
In the pivotal study, significantly more patients treated with levetiracetam than with placebo had a 50% reduction in the weekly number of myoclonic seizure days in both treatment and evaluation periods.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC. The licence holder has indicated their decision to resubmit.
Download detailed advice88KB (PDF)
Medicine details
- Medicine name:
- levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)
- SMC ID:
- 395/07
- Indication:
- as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 September 2007